

Manchester Experimental Cancer Medicine Centre

*The Experimental Cancer Medicine Team (ECMT); **The Manchester Centre for Cancer Biomarker Sciences (MCCBS) group





*The Christie NHS Foundation Trust and The National Institute for Health Research working in partnership within Manchester ECMC

Manchester ECMC supports early phase research from 'bench to bedside' through multi-disciplinary team collaborations across The Christie, University of Manchester (UoM) and Cancer Research UK Manchester Institute (CRUK MI)

Manchester ECMC metrics (2018)

- 1,332 patients consented across disease groups
- 1,106 patients enrolled (*inc non CTIMP)
- 115 studies



Manchester ECMC disease groups and cross cutting themes

Tumour Immunology and Inflammation Monitoring Laboratory**



- **GCP compliant TIIML** is up and running, analysing clinical samples from the TARGET & TRIBE study (immune characterisation post TKIs and pre immunotherapy)
- IHC assays developed for analysis of T-cell infiltrates and PD-L1 levels in tumour tissue

Radiation Related Research (RRR)




- The **MR-guided linear** accelerator at The Christie is 1 of only 7 in the world
- Combining magnetic resonance scanning with anti-tumour radiotherapy
- Early phase trials including biomarker experimental medicine & technology trials are open/planned

Training

- MRes Experimental Medicine (Cancer)
- CRUK MI/MCRC/UoM highly competitive PhD Programme
- Christie International Fellowship Programme



Patient and Public Involvement and Engagement (PPIE)



Patient voice



Patient showcase

Impact



- Utility of ctDNA to support patient selection for early phase clinical trials: the **TARGET** study (CI, Krebs) - **Nature Medicine** (April 2019)
- Brentuximab vedotin licensing/NICE adoption (Illidge/Radford)
- Entrectinib filing submitted to FDA/NICE (Krebs)
- SYD985 fast track (Thistlethwaite)